Real-world outcomes of lenvatinib plus pembrolizumab in intermediateand poor-risk metastatic renal cell carcinoma

Background. The combination of lenvatinib and pembrolizumab demonstrated significant efficacy in the phase 3 CLEAR study for metastatic renal cell carcinoma (RCC). However, poor-risk patients represented only a small proportion of the trial population.

Aim. This multicenter retrospective cohort study assessed the real-world efficacy and safety of lenvatinib plus pembrolizumab in patients with clear-cell metastatic RCC and intermediate or poor International Metastatic RCC Database Consortium risk.

Materials and methods. Outcomes included objective response rate, progression-free survival, overall survival, and safety. Sixty patients were analyzed, with a median age of 56 years. Poor risk was identified in 53 % of patients, and 90 % had metastases to ≥2 organs.

Results. Objective response rate was 48.33 %, disease control rate was 86.7 %, and median progression-free survival was 19.0 months. Grade ≥3 adverse events occurred in 25 % of patients, with 33.3 % requiring lenvatinib dose reductions.

Conclusion. Lenvatinib plus pembrolizumab demonstrated robust efficacy and a manageable safety profile in a real-world population with advanced disease and poor-risk features, consistent with outcomes reported in clinical trials.

1. Tsimafeyeu I., Zolotareva T., Varlamov S. et al. Five-year survival of patients with metastatic renal cell carcinoma in the Russian Federation: results from the RENSUR5 registry. Clin Genitourin Cancer 2017;15:e1069–72. DOI: 10.1016/j.clgc.2017.07.017

2. Tsimafeyeu I., Shatkovskaya O., Krasny S. et al. Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry. Cancer Rep (Hoboken) 2021;4:e1331. DOI: 10.1002/cnr2.1331

3. Barragan-Carrillo R., Saad E., Saliby R. et al. First and second-line treatments in metastatic renal cell carcinoma. Eur Urol 2025;87:143–54. DOI: 10.1016/j.eururo.2024.10.019

4. Motzer R.J., Porta C., Eto M. et al. Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma. Ann Oncol 2025;36:375–86. DOI: 10.1016/j.annonc.2024.12.003

5. Choueiri T.K., Eto M., Motzer R. et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol 2023;24:228–38. Erratum in: Lancet Oncol 2023;24:e146. DOI: 10.1016/S1470-2045(23)00049-9

6. Motzer R.J., Porta C., Eto M. et al.; CLEAR Trial Investigators. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study. J Clin Oncol 2024;42:1222–8. DOI: 10.1200/JCO.23.01569

7. Hara T., Suzuki K., Okamura Y. et al. Efficacy and safety of lenvatinib and pembrolizumab as first-line treatment for advanced renal cell carcinoma patients: real-world experience in Japan. Int J Clin Oncol 2024;29:1931–6. DOI: 10.1007/s10147-024-02633-w

8. Dutcher J.P., Flippot R., Fallah J., Escudier B. On the shoulders of giants: the evolution of renal cell carcinoma treatment – cytokines, targeted therapy, and immunotherapy. Am Soc Clin Oncol Educ Book 2020;40:1–18. DOI: 10.1200/EDBK_280817

9. Roskoski R. Jr. Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas. Pharmacol Res 2024;203:107181. DOI: 10.1016/j.phrs.2024.107181

10. Grünwald V., Powles T., Eto M. et al. Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-pluspembrolizumab and sunitinib arms. Front Oncol 2024;13:1343027. Erratum for: Front Oncol 2023;13:1223282. DOI: 10.3389/fonc.2023.1343027